信必可都保对重度COPD患者稳定期疗效影响

目的研究在基础平喘药物氨茶碱缓释片（舒弗美）、异丙托溴铵气雾剂（爱全乐）治疗基础上加用信必可都保对COPD缓解期患者的疗效及安全性。方法50名确诊为稳定期的重度COPD患者随机分为两组：爱全乐组26例，信必可组24例，分别使用舒弗美＋爱全乐、舒弗美＋爱全乐＋信必可都保治疗。观察比较治疗前及治疗后12周临床症状、生活质量评分、肺功能、病情变化及药物安全性。结果两组COPD受试者经治疗后临床症状、生活质量评分及肺功能均有明显改善（P〈0．05），而舒弗美＋爱全乐＋信必可联合治疗其改善作用更为显著（P〈0．05）。结论重度COPD稳定期患者应用舒弗美＋爱全乐＋信必可都保联合吸入治疗方案可提高疗效及改善预后。

Curative effect of budesonide and formoterol fumarate in the treatment of patients with severe chronic obstructive pulmonary disease at remission stage

Objective To investigate the curative effect and safety of budesonide and formoterol fumarate in the treatment of patients with severe chronic obstructive pulmonary disease at remission stage on the basis of other anti-asthmatic drugs such as theophylline sustained-release tablets （Slow-release Tbeopylline ） and ipratropium bromide aerosol （Atrovent）. Methods 50 patients with severe COPD at remission stage were randomly divided into two groups ： 26 patients as the control group were given theophylline sustained-release tablets and ipratropium bromide aerosol, and 24 patients as the experiment group were given budesonide and formoterol fumarate addition- ally. The clinical symptoms, quality of life, pulmonary function, condition change and drug safety were observed and compared before and after the 12 weeks＇ treatment. Results The clinical symptoms, quality of life and pulmonary function were all better improved in the two groups after the treatment （ P 〈 O. 05 ）, but the improvement was more pronounced in the experiment group than in the control group with statistical significance （ P 〈 0.05 ）. Conclusion The application of budesonide and formoterol fumarate plus slow-release Theopylline and Atrovent can improve the curative effect and prognosis in the treatment of patients with severe COPD at remission stage.